Safety of abatacept compared with other biologic and conventional synthetic disease-modifying antirheumatic drugs in patients with rheumatoid arthritis: data from an observational study

Table 3 Incidence rates for malignancy, infections and autoimmune disease outcomes by treatment

Outcomes	Abatacept		Other bDMARDs		csDMARDs
Outcomes	No. of events/ no. of patients	IR (95% CI)*	No. of events/ no. of patients	IR (95% CI)*	No. of events/ no. of patients	IR (95% CI)*
Overall malignancy^†	22/1099	0.76 (0.47, 1.15)	27/2592	0.50 (0.33, 0.72)	24/1093	0.86 (0.55, 1.27)
Lung	1/1099	0.012 (0.00, 0.07)	1/2592	0.02 (0.00, 0.10)	0/1093	0.00 (0.00, 0.13)
NMSC	20/1099	0.55 (0.40, 0.73)	25/2592	0.46 (0.30, 0.68)	20/1093	0.71 (0.43, 1.10)
Hospitalized infections	37/1496	1.63 (1.15, 2.24)	135/3490	1.78 (1.49, 2.11)	77/1520	1.90 (1.50, 2.38)
Opportunistic	2/1496	0.09 (0.01, 0.31)	6/3490	0.08 (0.03, 0.17)	3/1520	0.07 (0.02, 0.21)
Pneumonia	13/1496	0.57 (0.30, 0.97)	80/3490	1.04 (0.82, 1.29)	50/1520	1.03 (0.79, 1.33)
Lupus	1/1496	0.04 (0.00, 0.24)	0/3490	0.00 (0.00, 0.05)	3/1520	0.07 (0.02, 0.21)
Psoriasis	15/1496	0.66 (0.37, 1.09)	30/3490	0.39 (0.26, 0.55)	15/1520	0.36 (0.20, 0.59)
Multiple sclerosis^†	1/1484	0.04 (0.00, 0.24)	0/3471	0.00 (0.00, 0.05)	0/1515	0.00 (0.00, 0.09)
All hospitalizations	637/1496	28.83 (26.64, 31.16)	2001/3490	28.26 (27.03, 29.53)	1292/1520	32.53 (30.78, 34.36)
All deaths^‡	128/1496	2.99 (2.49, 3.55)	162/3490	2.16 (1.84, 2.52)	117/1520	2.78 (2.30, 3.33)

There were no events for breast cancer, lymphoma or tuberculosis in any treatment group
*Per 100 patient-years
^†Patients with prior history of malignancy or multiple sclerosis were excluded
^‡Deaths from all causes within 1 year of last use of abatacept or of last study observation for control subjects
bDMARD biologic disease-modifying antirheumatic drug, CI confidence interval, csDMARD conventional synthetic disease-modifying antirheumatic drug, IR incidence rate, NMSC non-melanoma skin cancer

ISSN: 1478-6362